The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Table 3 Univariate and multivariate analysis of comorbidities correlating with PFS and OS

Covariate	Univariate analysis			Multivariate analysis
	p-value	HR	95% CI	p-value	HR	95% CI
PFS
T2D	0.009	1.810	1.104–2.969	0.048	1.833	1.005–3.345
Peripheral vascular disease	0.664	0.818	0.446–1.499	0.887	0.961	0.555–1.662
Dementia	0.092	0.587	0.081–4.233	0.162	2.149	0.734–6.289
Renal disease	0.823	0.529	0.129–2.165	0.510	0.666	0.199–2.231
Obesity	0.060	1.913	1.121–3.263	0.451	1.230	0.717–2.109
Hypercholesterolemia	0.842	0.479	0.150–1.527	0.829	0.913	0.402–2.073
Hypertension	0.064	1.204	0.615–2.361	0.941	1.029	0.480–2.205
Thyroiditis	0.306	1.543	0.666–3.576	0.867	0.927	0.384–2.238
Chronic pulmonary disease	0.289	0.282	0.069–1.154	0.126	0.498	0.204–1.216
Other comorbidities	0.7791	1.112	0.654–1.890	0.507	1.180	0.722–1.929
OS
T2D	0.018	1.740	1.142–2.651	0.009	2.377	1.240–4.557
Peripheral vascular disease	0.517	0.894	0.541–1.479	0.347	0.728	0.376–1.410
Dementia	0.597	2.389	0.866–6.590	0.386	0.408	0.053–3.093
Renal disease	0.376	0.892	0.327–2.430	0.263	0.393	0.076–2.019
Obesity	0.017	1.563	0.980–2.495	0.044	1.841	1.014–3.341
Hypercholesterolemia	0.213	0.929	0.450–1.917	0.334	0.527	0.143–1.934
Hypertension	0.586	1.645	0.971–2.786	0.212	0.551	0.216–1.406
Thyroiditis	0.311	1.463	0.705–3.033	0.417	1.517	0.554–4.153
Chronic pulmonary disease	0.078	0.638	0.278–1.463	0.046	0.228	0.053–0.977
Other comorbidities	0.692	1.066	0.681–1.668	0.252	1.388	0.791–2.435

ISSN: 1479-5876